Abbott Laboratories Aktie News

Abbott Laboratories has been essentially flat over the last 15 months, underperforming the S&P 500's 17.5% total return. Q3 2025 results showed normalized EPS in line at $1.30, with revenue up nearly 7% year-over-year, but missing consensus by $20M. Most of the segments saw healthy increases, particularly in the International regions in Q3; hopefully, we'll see the same in Q4 next week.

NEW YORK  and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Abbott Laboratories (NYSE: ABT) doesn't just pay dividends.

Dividend aristocrats get plenty of attention, but most of the time the spotlight falls on the big names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), and Procter & Gamble (NYSE:PG), among others.

Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent...

The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease (the "Company") announced today that Sentinel Opportunity Fund I, LP (the "Fund") has closed on the acquisitions of two mission-critical commercial properties leased to Abbott Laboratories and V3 ...

ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.

Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4 Ab...